Patents by Inventor Lydia Jasmin Hanisch
Lydia Jasmin Hanisch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11787873Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: January 16, 2020Date of Patent: October 17, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Patent number: 11788205Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens.Type: GrantFiled: June 19, 2020Date of Patent: October 17, 2023Inventors: Christian Klein, Ekkehard Moessner, Lydia Jasmin Hanisch, Wei Xu, Camille Loise Sophie Delon, Diana Darowski, Christian Jost, Vesna Pulko
-
Publication number: 20230322957Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.Type: ApplicationFiled: November 21, 2022Publication date: October 12, 2023Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
-
Publication number: 20220411534Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: November 4, 2021Publication date: December 29, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Patent number: 11192957Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: December 20, 2018Date of Patent: December 7, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Publication number: 20210230278Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 17, 2020Publication date: July 29, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
-
Publication number: 20210025894Abstract: The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.Type: ApplicationFiled: October 2, 2020Publication date: January 28, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Diana DAROWSKI, Camille Loise Sophie DELON, Lydia Jasmin HANISCH, Christian KLEIN, Christian JOST, Ekkehard MOESSNER, Vesna PULKO, Wei XU
-
Publication number: 20210018509Abstract: The present invention generally relates to diagnostic assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter cell assays to analyze samples, in particular patient samples, to diagnose cancer by quantifying the expression of tumor antigens and/or predicting clinical response to cancer immunotherapies. A further aspect of the present invention is to improve safety of e.g., cancer immunotherapies.Type: ApplicationFiled: October 2, 2020Publication date: January 21, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Diana DAROWSKI, Camille Loise Sophie DELON, Lydia Jasmin HANISCH, Christian JOST, Christian KLEIN, Ekkehard MOESSNER, Vesna PULKO, Wei XU
-
Publication number: 20200318105Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T cell) assays to test antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a target antigen, e.g., tumor associated antigens.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Christian KLEIN, Ekkehard MOESSNER, Lydia Jasmin HANISCH, Wei XU, Camille Loise Sophie DELON, Diana DAROWSKI, Christian JOST, Vesna PULKO
-
Publication number: 20200316128Abstract: The present invention generally relates to specificity assays using cell cultures, in particular to chimeric antigen receptor (CAR) expressing reporter T (CAR-T) cell assays to test novel antigen binding moieties in different formats. Furthermore, the present invention relates to the use of CAR-T cells, transfected/transduced with an engineered chimeric antigen receptor (CAR) comprising a target antigen binding moiety capable of specific binding to a recognition domain of an antigen binding molecule. The invention also relates to methods and kits for specificity testing of a candidate antigen binding moiety and/or nucleic acid molecules and vectors expressing engineered CARs.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Christian KLEIN, Ekkehard MOESSNER, Lydia Jasmin HANISCH, Wei XU, Camille Loise Sophie DELON, Diana DAROWSKI, Christian JOST, Vesna PULKO
-
Publication number: 20200291131Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: January 16, 2020Publication date: September 17, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Publication number: 20200283545Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.Type: ApplicationFiled: March 17, 2020Publication date: September 10, 2020Inventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
-
Patent number: 10683369Abstract: The invention relates to new antibodies against BCMA, their manufacture and use.Type: GrantFiled: August 3, 2016Date of Patent: June 16, 2020Assignee: EngMab SàrlInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Camille Delon, Lydia Jasmin Hanisch, Anne Freimoser-Grundschober, Christian Klein, Ekkehard Moessner, Samuel Moser, Pablo Umana, Tina Weinzierl
-
Patent number: 10584178Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: June 17, 2016Date of Patent: March 10, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Rebecca Croasdale-Wood, Lydia Jasmin Hanisch, Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Claudio Sustmann, Pablo Umana
-
Publication number: 20190248916Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 20, 2018Publication date: August 15, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Joerg Benz, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Lydia Jasmin Hanisch, Alexander Bujotzek, Wei Xu
-
Patent number: 10253104Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.Type: GrantFiled: August 3, 2015Date of Patent: April 9, 2019Assignee: ENGMAB AGInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20170306036Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.Type: ApplicationFiled: August 3, 2015Publication date: October 26, 2017Applicant: ENGMAB AGInventors: Minh Diem VU, Klaus STREIN, Oliver AST, Marina BACAC, Lydia Jasmin HANISCH, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Samuel MOSER, Ramona MURR, Pablo UMANA, Sabine JUNG-IMHOF, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg REGULA, Wolfgang SCHAEFER
-
Publication number: 20150218244Abstract: The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). More particularly, the invention concerns fusion proteins of antibodies and mutant IL-10 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.Type: ApplicationFiled: February 4, 2015Publication date: August 6, 2015Inventors: Thomas Emrich, Pablo Umana, Ekkehard Moessner, Ralf Hosse, Jens Fischer, Lydia Jasmin Hanisch, Daigen Xu